These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 34544029

  • 1. Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents.
    Pathak A, Pandey V, Raj Pokharel Y, Devaraji V, Ali A, Haider K, Saad S, Dewangan RP, Siddiqui N, Shahar Yar M.
    Bioorg Chem; 2021 Nov; 116():105358. PubMed ID: 34544029
    [Abstract] [Full Text] [Related]

  • 2. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
    Alkamaly OM, Altwaijry N, Sabour R, Harras MF.
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
    Wei H, Duan Y, Gou W, Cui J, Ning H, Li D, Qin Y, Liu Q, Li Y.
    Eur J Med Chem; 2019 Nov 01; 181():111552. PubMed ID: 31387063
    [Abstract] [Full Text] [Related]

  • 4. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
    Mghwary AE, Gedawy EM, Kamal AM, Abuel-Maaty SM.
    J Enzyme Inhib Med Chem; 2019 Dec 01; 34(1):838-852. PubMed ID: 30919701
    [Abstract] [Full Text] [Related]

  • 5. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM, Hamdi A, Bayoumi WA, Elgazar AA, Nasr MNA.
    Bioorg Chem; 2024 Jul 01; 148():107437. PubMed ID: 38749114
    [Abstract] [Full Text] [Related]

  • 6. Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFRWT, EGFRT790M tyrosine kinases and COX-2 Inhibitors, with anti-cancer and anti-inflammatory activities.
    Fadaly WAA, Nemr MTM, Kahk NM.
    Bioorg Chem; 2024 Jun 01; 147():107403. PubMed ID: 38691909
    [Abstract] [Full Text] [Related]

  • 7. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.
    Ezelarab HAA, Ali TFS, Abbas SH, Sayed AM, Beshr EAM, Hassan HA.
    Mol Divers; 2024 Apr 01; 28(2):563-580. PubMed ID: 36790582
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM, El-Gaby MSA, El-Adl K, Abd El-Sattar NEA.
    Bioorg Chem; 2020 Nov 01; 104():104350. PubMed ID: 33142416
    [Abstract] [Full Text] [Related]

  • 14. Benzimidazole-oxindole hybrids: A novel class of selective dual CDK2 and GSK-3β inhibitors of potent anticancer activity.
    Abdel-Mohsen HT, Syam YM, Abd El-Ghany MS, Abd El-Karim SS.
    Arch Pharm (Weinheim); 2024 Oct 01; 357(10):e2300721. PubMed ID: 39041665
    [Abstract] [Full Text] [Related]

  • 15. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE, Farouk NA, El-Sayed EH, Mahdy ARE.
    Life Sci; 2021 Jul 15; 277():119531. PubMed ID: 33887348
    [Abstract] [Full Text] [Related]

  • 16. Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies.
    Hassan RM, Ali IH, El Kerdawy AM, Abo-Elfadl MT, Ghannam IAY.
    Bioorg Chem; 2024 Nov 15; 152():107728. PubMed ID: 39178704
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers.
    Kassab AE, Gedawy EM, Hamed MIA, Doghish AS, Hassan RA.
    J Enzyme Inhib Med Chem; 2021 Dec 15; 36(1):922-939. PubMed ID: 33896327
    [Abstract] [Full Text] [Related]

  • 19. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM, AboulWafa OM, Baghdadi HH, Abd El Razik HA, Sedra SMY, Shamaa MM.
    Bioorg Chem; 2021 Oct 15; 115():105208. PubMed ID: 34365057
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
    Yuan X, Yang Q, Liu T, Li K, Liu Y, Zhu C, Zhang Z, Li L, Zhang C, Xie M, Lin J, Zhang J, Jin Y.
    Eur J Med Chem; 2019 Oct 01; 179():147-165. PubMed ID: 31252306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.